Lee Chi-Jen, Lee Lucia H, Lu Cheng-Hsiung, Huang Yi-Jiun, Chu Mong-Ling
Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA.
Acta Paediatr Taiwan. 2006 Jan-Feb;47(1):7-13.
The development of vaccines has been one of the most important achievement in preventive medicine. As the incidence of vaccine-preventable diseases is reduced by immunization, general public becomes increasingly concerned about the safety associated with vaccine. Vaccine safety is extensively evaluated through animal safety studies, clinical trials, during manufacturing processes, and postlicensure surveillance. Safety monitoring in postlicensure surveillance has relied on passive reporting system and epidemiological studies, including Vaccine Adverse Event Reporting System (VARES), Vaccine Safety Datalink (VSD) Project and others. Approximately 10,000 reports per year are submitted to VAERS. About 15% of these describe serious events and 85% of reports are classified as not-serious events. The system analyzed frequently reported adverse reactions, rare events, intussusception after rotavirus vaccine, cases of sudden infant death syndrome (SIDS), and safety of various vaccines. The evidence for a causal relationship with vaccines can be classified into five categories: no evidence, evidence was inadequate to accept or reject, evidence favors rejection, evidence favors a causal relationship, and evidence established. Future challenges involve improving survey and monitoring system of adverse events after immunization, enhancing vaccine safety research and vaccine risk communication, and possibility of increased reactogenicity in new and combined vaccines.
疫苗的研发一直是预防医学最重要的成就之一。随着通过免疫接种降低了疫苗可预防疾病的发病率,公众越来越关注疫苗的安全性。疫苗安全性通过动物安全性研究、临床试验、生产过程以及上市后监测进行广泛评估。上市后监测中的安全性监测依赖于被动报告系统和流行病学研究,包括疫苗不良事件报告系统(VAERS)、疫苗安全数据链(VSD)项目等。每年约有10000份报告提交给VAERS。其中约15%描述严重事件,85%的报告被归类为非严重事件。该系统分析了频繁报告的不良反应、罕见事件、轮状病毒疫苗接种后的肠套叠、婴儿猝死综合征(SIDS)病例以及各种疫苗的安全性。与疫苗存在因果关系的证据可分为五类:无证据、证据不足以接受或拒绝、证据倾向于拒绝、证据支持因果关系以及证据确凿。未来的挑战包括改进免疫接种后不良事件的调查和监测系统、加强疫苗安全性研究和疫苗风险沟通,以及新型和联合疫苗中反应原性增加的可能性。